Published peer-reviewed research shows that Cognitive FX treatment leads to meaningful symptom reduction in post-concussion symptoms for 77% of study participants. Cognitive FX is the only PCS clinic with third-party validated treatment outcomes.
READ FULL STUDY
If your depression hasn't responded to multiple antidepressants, you're not out of options — even if it feels that way. Only about one-third of people with major depressive disorder achieve full remission from their first medication — meaning the majority need to try something else. For those who've been through several treatments without success, finding the right path forward can feel overwhelming.
This guide covers evidence-based treatments for treatment-resistant depression (TRD) — brain stimulation therapies like TMS and ECT, rapid-relief options like ketamine and Spravato, psychotherapy approaches, and medication strategies. For each, you'll find actual remission rates, how long benefits last, what maintenance looks like, and cost estimates.
Note: Cognitive FX offers fMRI-guided accelerated TMS — an off-label equivalent to Stanford's SAINT protocol — with approximately 79% remission rates. If you'd like to see whether you're a candidate, take our short quiz or call 385-334-6093.
| Treatment | Remission Rate | Time to Relief | Maintenance | Year 1 Cost (Approx.) |
|---|---|---|---|---|
| fMRI-guided accelerated TMS (SAINT-style) | 70–79% | Days | Brief retreatment every few months as needed | $7,000–$36,000 |
| Standard rTMS | 30–36% | 4–6 weeks | Monthly to biweekly ongoing | $6,000–$15,000 |
| ECT | 48% | 1–2 weeks | Monthly sessions with anesthesia | $5,000–$15,000 |
| IV Ketamine | 50–70% response | Hours to days | Weekly infusions indefinitely | $15,000–$25,000 |
| Esketamine (Spravato) nasal spray | 50–70% response | Hours to days | Weekly/biweekly indefinitely | $18,000–$32,000 |
| Psychotherapy (CBT/MBCT) | 40–48% | 8–12 weeks | Potentially self-maintaining | $1,200–$5,400 |
| Continued antidepressant medications | Varies | N/A (already tried) | Daily pills | $500–$3,000 |
No single treatment is universally "best." The right choice depends on your symptom severity, how quickly you need relief, your treatment history, and practical factors like cost and access. The highest remission rates often come from combination approaches.
Treatment-resistant depression isn't a separate diagnosis — it describes major depression that hasn't responded adequately to standard treatments. You're generally considered to have TRD if you've tried two or more antidepressant medications from different classes, at adequate doses, for at least 6–8 weeks each, without sufficient improvement.
More common than most people realize:
These numbers explain why finding alternatives to continued medication trials becomes essential for many patients.
Depression that doesn't respond to multiple medications often reflects more than a simple imbalance in neurotransmitters like serotonin, norepinephrine, or dopamine. Research points to several factors:
This understanding is what makes treatments targeting the brain directly — like transcranial magnetic stimulation — potentially more effective than trying yet another medication. For more on this topic, see our guide on why antidepressant medications stop working.
Brain stimulation (also called neuromodulation) therapies work by directly stimulating nerve cells in the brain regions involved in mood regulation. Unlike medications, which work indirectly through neurotransmitter systems, these interventions target dysfunctional neural circuits where they originate.
Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) represents the most significant advance in depression treatment in recent years. If you've heard about its remarkable success rates and wondered whether they're real — and whether they last — here's what the research shows.
This isn't just "faster TMS." Three innovations set it apart:
1. Personalized brain mapping. Instead of using scalp landmarks (which have less than 50% accuracy), the protocol uses functional MRI to map your unique brain networks. The imaging identifies the exact spot in your left dorsolateral prefrontal cortex (DLPFC) that's most disconnected from deeper mood-regulating regions. Neuronavigation software then guides magnet placement with near-100% accuracy — within 1–2mm, versus up to 2cm error with conventional approaches.
2. Accelerated, high-dose protocol. You receive 1,800 pulses per session, 10 sessions per day, for 5 consecutive days — 90,000 total pulses. Standard rTMS delivers 18,000–20,000 over 6–9 weeks. This concentrated dosing creates more powerful neural circuit changes.
3. Optimized pulse delivery. The protocol uses intermittent theta burst stimulation (iTBS), an FDA-approved pattern that mimics the brain's natural rhythms. Each session takes about 10 minutes rather than 30–40 minutes for standard rTMS.
For a deeper comparison, see our article on rTMS vs. iTBS.
The results from clinical trials are striking:
Compare this to the ~33% remission rate for SSRIs and antidepressants from the STAR*D study. For more context on TMS success rates across different protocols, see our dedicated comparison.
A 2025 durability study published in Brain Stimulation provides the most comprehensive answer.
Without maintenance treatment: Of patients who achieved remission, 47% maintained it at 3 months. Median time patients stayed well was about 3.5 months — comparable to ECT and standard TMS without follow-up care.
With personalized maintenance: A 2024 continuation therapy study found that 86% of participants maintained remission over 12 months when retreatment was triggered by early warning signs. Most retreatment courses required only 1–2 days.
This means potentially staying well with just a couple of treatment days every few months — rather than daily medications, weekly ketamine infusions, or monthly ECT sessions under anesthesia.
Good candidates have typically:
For a detailed breakdown, see Is SAINT TMS right for me?
The initial 5-day course costs $7,000–$36,000 depending on the provider. Medicare began covering SAINT at $19,703 in July 2025. Currently, fewer than 20 clinics in the US offer the complete protocol with fMRI mapping and neuronavigation.
Cognitive FX offers fMRI-guided accelerated TMS at $7,000–$12,000 — see the Cost and Insurance section for details, or our article on SAINT treatment cost.
FDA-approved since 2008, standard repetitive transcranial magnetic stimulation uses magnetic pulses to stimulate nerve cells in brain regions involved in mood regulation. It remains an important option, particularly if you prefer a gradual approach, want insurance coverage, or can't access an accelerated protocol.
The typical protocol involves daily weekday sessions for 6–9 weeks (36–40 total sessions), with about 3,000 pulses per session taking 30–40 minutes. Target location is determined by scalp measurements rather than individual brain imaging. The treatment is non-invasive — no surgery, anesthesia, or sedation required.
For a comparison of the two main TMS approaches, see rTMS vs. deep TMS.
While one-third achieving full remission may seem modest, for patients who've already failed multiple antidepressants, this represents meaningful improvement over trying yet another medication with diminishing odds. See how long TMS takes to work for more on the timeline.
TMS side effects are generally mild: headache and scalp discomfort during sessions are most common. There's no sedation, no memory effects, and you can drive yourself home. Some patients experience a temporary dip in mood during the first weeks — known as the TMS dip — before improvement begins.
For a detailed overview of what to expect, see what does TMS feel like? and our guide to TMS pros and cons.
With continuation medications and monitoring: 50% sustained response at 1 year, 20% relapse at 6 months. Without any follow-up: 80% relapse. Most patients need gradual tapering from 3x weekly to monthly sessions, potentially for years. When symptoms worsen, reintroducing TMS shows an 84.2% success rate. (source)
$6,000–$12,000 for 36–40 sessions. Most insurance companies cover standard TMS after documented medication failures (typically 4 different medications). Out-of-pocket costs with insurance are often $1,000–$3,000. See does insurance cover TMS therapy? and TMS treatment costs for details.
Despite decades of newer treatments, ECT remains the most powerful option for certain types of severe depression. Understanding when it's truly the best choice — and when alternatives work as well — matters.
ECT makes the most sense for:
ECT induces a brief, controlled seizure under general anesthesia using a mild electrical current, triggering widespread neurochemical changes:
(source)
The most common concern is memory. Short-term memory effects are common during treatment, and most resolve within weeks after the course ends. Some patients (roughly 30–50%) report persistent memory gaps for events around the treatment period, though long-term studies show no progressive cognitive decline with maintenance ECT.
Every session requires general anesthesia (an anesthetic is used), which means fasting beforehand, an IV, recovery time, and someone to drive you home. Total time per session: 2–3 hours.
ECT carries the most risk of the treatments discussed here, followed by ketamine. The mortality rate is approximately 1 in 10,000 treatments — comparable to general anesthesia for minor procedures.
Without any follow-up: 84% relapse within 6 months — the highest relapse rate of any depression treatment. With continuation medications (nortriptyline plus lithium): 39% relapse at 6 months. With both continuation ECT and medications: only 7% relapsed at 2 years. (source 1, CORE study)
Plan on monthly maintenance ECT for at least a year, possibly longer, alongside optimized medications.
Per session: $300–$1,000. Acute course (6–12 sessions): $2,500–$5,000. Maintenance per year: $3,600–$12,000. Generally well-covered by insurance.
Several additional brain stimulation approaches exist, though with more limited evidence for TRD:
Vagus nerve stimulation (VNS) — An implanted device sends mild electrical signals through the vagus nerve to brain regions involved in mood regulation. FDA-approved for TRD, but requires surgery to implant. Response develops slowly over months. Typically reserved for patients who haven't responded to other interventions.
Deep brain stimulation (DBS) — Involves surgically implanting electrodes in specific brain regions. Still largely experimental for depression, with clinical trials ongoing. Currently an inpatient procedure with significant surgical risk factors.
Transcranial direct current stimulation (tDCS) — Uses a weak electrical current applied through scalp electrodes. Non-invasive and inexpensive, but evidence for TRD is weaker than for TMS or ECT. May have a role as an adjunct treatment.
For a broader overview of all options, see our guide to brain stimulation treatments for depression.
If you need relief measured in hours or days rather than weeks, ketamine-based treatments offer the fastest-acting options for TRD. Speed comes with trade-offs in durability and ongoing commitment.
Unlike antidepressant medications that target monoamine neurotransmitters (serotonin, norepinephrine, dopamine), ketamine works through the glutamate system and NMDA receptors — a completely different mechanism that explains why it works when other treatments have failed and why it acts so quickly.
Administered by infusion over 40 minutes in a clinic, typically at 0.5–1.0 mg/kg. It is not FDA-approved for depression (off-label use), though it has a longer track record for depression treatment than esketamine. An anesthetic agent by origin, ketamine produces dissociative effects during infusion.
(source)
Ketamine's effects are powerful but remarkably short-lived without ongoing treatment:
To maintain benefits, most patients need weekly infusions indefinitely — 52+ clinic visits per year.
Per infusion: $400–$800. Initial course (6 infusions): $2,400–$4,800. Weekly maintenance: $20,800–$41,600 per year. Usually NOT covered by insurance (off-label use).
For a detailed comparison, see ketamine vs. TMS for depression and can ketamine stop working?
Esketamine is the S-enantiomer of ketamine, FDA-approved specifically for TRD since 2019 as a nasal spray. It must be combined with an oral antidepressant and self-administered at a clinic under supervision, with 2-hour monitoring after each dose.
Similar to IV ketamine: 50–70% response rate. The SUSTAIN-1 trial demonstrated 51% relapse risk reduction for stable remitters compared to stopping treatment. Real-world 6-month data from the ICEBERG study showed a 49.7% response rate and 27.7% remission rate.
Long-term safety data extends to 6.5 years of continuous treatment.
Per session: $590–$885 depending on dose. Total first year: $18,000–$32,000. Often covered by insurance with prior authorization, though copays can be substantial.
For a head-to-head comparison, see TMS vs. Spravato.
Evidence-based psychotherapy may be the most overlooked effective treatment for TRD. Unlike interventions that provide relief as long as you continue them, talk therapy aims to build lasting skills that protect you even after treatment ends.
1. Cognitive behavioral therapy (CBT) helps identify and change distorted thinking patterns and behaviors that maintain depression. The large CoBalT trial tracked 469 TRD patients: at nearly 4 years, CBT recipients maintained a 43% response rate with lasting improvements in functioning — well after therapy ended. Typical course: 12–18 sessions over 3–4 months. (source)
2. Cognitive Behavioral Analysis System of Psychotherapy (CBASP) was developed specifically for chronic depression, focusing on interpersonal patterns. Intensive inpatient programs showed 84% response and 44% remission rates, with 48% maintaining sustained response at one year. Particularly effective for those with early childhood trauma. (source)
3. Mindfulness-based cognitive therapy (MBCT) combines meditation with cognitive therapy, teaching you to relate differently to depressive thoughts. For TRD, response rates actually improved from 30% at 8 weeks to 44% at 52 weeks — benefits consolidated over time rather than fading. (source)
This is where psychotherapy stands apart. Meta-analyses of CBT for depression show 31.6% relapse rates versus 41.3% for controls. When antidepressants are discontinued, relapse rates jump to 74–77%, but after CBT, rates are significantly lower. The skills remain after treatment ends. (source)
Research in the American Journal of Psychiatry concluded that psychotherapy may yield greater durability of treatment gains than pharmacotherapy — you become, in effect, your own therapist.
The most effective treatment for many patients combines both: brain stimulation rapidly reduces depressive symptoms, making you more able to engage in therapy. Therapy provides tools to handle stressors that might otherwise trigger relapse. Together, they achieve better long-term outcomes than either alone.
At Cognitive FX, cognitive behavioral therapy is incorporated alongside accelerated TMS, which research suggests improves remission rates by approximately 19% compared to TMS alone.
12–18 sessions at $100–$300 each: $1,200–$5,400 total. Most insurance covers psychotherapy with copays. Unlike other treatments, therapy's benefits don't disappear when you stop — the skills remain.
If you're reading this guide, you've likely tried multiple antidepressant medications from different classes without adequate success. The question is whether medications still have a role in your treatment plan — and the answer is usually yes, just not as the primary intervention.
As maintenance after brain stimulation. Studies consistently show that continuing antidepressants after achieving remission with TMS or ECT significantly improves durability. You're not relying on the medication to fix your depression — you're using it to help maintain improvements created by brain stimulation. Combining antidepressants and TMS therapy can be more effective than either alone.
Augmentation strategies. Adding certain medications to boost antidepressant response:
Switching classes. SSRIs and SNRIs are the most commonly prescribed antidepressants, but different classes target different neurotransmitter systems. MAOIs (monoamine oxidase inhibitors) are underutilized older medications that can be remarkably effective for highly resistant depression. The dietary restrictions make them inconvenient, but for some patients, switching to a different antidepressant class makes a meaningful difference. See what to do when SSRIs don't work.
Pharmacogenomic testing. Genetic testing can identify which medications you metabolize effectively, potentially explaining past failures and guiding better choices.
The STAR*D study tracked over 4,000 patients through sequential medication trials and found sobering results: 47% of remitters relapsed within 1 year despite continuing their medication. For those who responded without full remission: 68% relapsed. With each failed trial, the odds of the next one working dropped dramatically. Treatment resistance tends to worsen with continued unsuccessful medication trials.
When you've already failed multiple adequate medication trials, the probability that the next one will work is very low. This is when exploring alternative treatments for depression — whether brain stimulation, intensive psychotherapy, or combinations — becomes important.
For more context, see our articles on fast-acting antidepressant options and what to do when therapy isn't working for depression.
Getting well is only half the challenge. Understanding how long each treatment's benefits last — and what maintenance is required — should be central to your decision.
| Treatment | Natural Durability |
|---|---|
| Psychotherapy (CBT/MBCT) | 48–70% maintain response at 1 year; skills remain indefinitely |
| fMRI-guided accelerated TMS | 47% maintain remission at 3 months (median: ~3.5 months) |
| Standard rTMS | 50% sustained response at 1 year (with medications) |
| Continued antidepressants (in TRD) | 47–53% relapse at 1 year despite medication |
| ECT without follow-up | 84% relapse within 6 months |
| Ketamine/esketamine | 2–3 weeks median; 68–75% relapse within 6 months |
| Treatment + Maintenance | Outcome | What's Required |
|---|---|---|
| fMRI-guided TMS + personalized retreatment | 86% maintained remission at 12 months | ~15 treatment days/year; most retreatments 1–2 days |
| ECT + continuation ECT + medications | 93% relapse-free at 2 years | Monthly ECT + daily medications indefinitely |
| Standard rTMS + maintenance sessions | 80–90% avoid relapse | Monthly/biweekly TMS + medications indefinitely |
| Esketamine + maintenance dosing | 51–70% relapse risk reduction | Weekly/biweekly clinic visits indefinitely |
| Psychotherapy + medications | Superior to either alone | Skills-based; potentially self-maintaining |
Key takeaway: Psychotherapy offers the best "maintenance-free" durability. Ketamine shows the poorest — benefits evaporate within weeks of stopping. Brain stimulation therapies fall between, with fMRI-guided protocols requiring the lightest maintenance burden.
| Treatment | Upfront | Maintenance (Year 1) | Total Year 1 | Insurance |
|---|---|---|---|---|
| fMRI-guided TMS (CFX) | $7,000–$12,000 | Brief retreatments as needed | $7,000–$15,000 | Self-pay; Medicare covers SAINT at $19,703 |
| fMRI-guided TMS (Magnus SAINT) | $28,000–$36,000 | $5,000–$8,000 | $33,000–$44,000 | Medicare; limited private coverage |
| Standard rTMS | $6,000–$12,000 | $1,800–$7,200 | $7,800–$19,200 | Usually covered after medication failures |
| ECT | $2,500–$5,000 | $3,600–$12,000 | $6,100–$17,000 | Generally well-covered |
| IV Ketamine | $2,400–$4,800 | $20,800–$41,600 | $23,200–$46,400 | Usually NOT covered |
| Esketamine (Spravato) | $4,720–$7,080 | $14,000–$23,000 | $18,720–$30,080 | Often covered; high copays common |
| Psychotherapy | $1,200–$5,400 | $0–$1,200 (optional) | $1,200–$6,600 | Usually covered with copays |
| Antidepressants | $0–$500 | $500–$3,000 | $500–$3,500 | Generally covered |
Worth noting: Ketamine may be the most expensive option long-term due to indefinite weekly maintenance. And the cheapest options (continued antidepressants) may cost more over years when they don't work — factoring in lost productivity, additional treatments, and continued suffering.
Direct medical costs are only part of the picture. TRD can cost $10,000–$20,000+ per year in lost work productivity alone. How much is it worth to get your mental health back months or years sooner?
For more on financing, see does insurance cover TMS therapy? and TMS depression treatment costs.
Severity and urgency. Mild-moderate TRD: consider psychotherapy or standard TMS first. Severe TRD with significant impairment: accelerated TMS, ECT, or ketamine for rapid relief. Active suicidal crisis: ECT or esketamine (which has an FDA-approved indication for suicidal ideation).
Treatment history. Failed 1–2 medications: standard TMS or intensive therapy may suffice. Failed 4+ medications: consider fMRI-guided TMS, ECT, or ketamine. Failed standard TMS: accelerated TMS or ECT. Never had adequate psychotherapy: try evidence-based therapy before more intensive interventions.
Practical considerations. Can take a week off: accelerated TMS is ideal. Can accommodate daily appointments for 6–9 weeks: standard rTMS. Need ongoing weekly commitment: ketamine may fit your schedule. Limited budget but good insurance: standard TMS or ECT.
Risk factors and comorbidities. Coexisting conditions — mood disorders like bipolar disorder, personality disorder, anxiety, substance use concerns, or chronic pain — influence which treatments are safest and most effective. Some healthcare providers recommend additional psychiatric evaluation before pursuing brain stimulation if there's diagnostic uncertainty.
You've failed 2–3 antidepressants and never had good therapy: Start with intensive evidence-based psychotherapy. Many "treatment-resistant" patients never received adequate, specialized therapy. The durability and skill-building make it worth trying first.
Severe depression, 4+ medication failures, significant impairment: fMRI-guided accelerated TMS for rapid remission, combined with medication continuation and therapy to maximize durability.
Standard TMS didn't work, can't access accelerated TMS: ECT with comprehensive continuation plan, or ketamine for rapid relief followed by a transition to a maintenance protocol.
Chronic depression for years, functioning but suffering: Comprehensive evaluation at a specialized center. Consider intensive psychotherapy or combination approaches for best long-term outcomes.
Working with a psychiatry specialist experienced in treatment-resistant depression — rather than a general practitioner — often yields better treatment matching for highly resistant cases.
Most depression treatment follows a trial-and-error approach: try a medication, wait 6–8 weeks, adjust, repeat. That process can stretch on for years. At Cognitive FX, we take a different approach — one built on precision and personalization rather than guesswork.
Our depression treatment begins with an fMRI scan that maps your individual brain activity, identifying the precise location of the DLPFC — the region involved in mood regulation — before any stimulation takes place. This is the same core principle behind Stanford's SAINT protocol, delivered as an off-label equivalent at a fraction of the cost.
The protocol:
For a full safety overview, see our article on whether TMS is safe. If you're concerned about side effects, see can TMS make depression worse? and can TMS make anxiety worse?
If you've been through multiple antidepressants without adequate relief, CFX's fMRI-guided TMS may be worth exploring. You can take a short quiz to see if you're a likely candidate, schedule a consultation, or call 385-334-6093 to speak with someone directly.
If you're researching TMS specifically, these guides may help:
SAINT/Accelerated TMS:
Standard TMS:
ECT:
Ketamine/Esketamine:
Psychotherapy:
Antidepressants:
DISCLAIMER: SAINT™ is a trademark of The Board of Trustees of the Leland Stanford Junior University ("Stanford") and has exclusively licensed such mark to Magnus Medical. Cognitive FX is neither endorsed by Stanford nor utilizes Magnus Medical equipment nor claims to be offering the SAINT protocol as prescribed by Stanford University et al. or Magnus Medical. We provide fMRI-guided intermittent theta burst TMS with target locations determined by fMRI and our prescribing physician.
Thomas Tervort holds a Doctorate of Nursing Practice from Rocky Mountain University of Health Professions. Prior to earning his doctorate Dr. Tervort worked in cardiology performing diagnostic testing before becoming a Registered Nurse and working with cardiac and cardiothoracic surgery patients in the Intensive Care Unit. Following this he worked in neurosurgery educating and addressing the needs of surgical patients while he completed his doctoral degree.
Anxious depression, clinically referred to as mixed anxiety depressive disorder (MADD), is a challenging condition to treat. Standard approaches — such as antidepressant medication and psychotherapy...
If you've struggled with depression that hasn't responded to medications, you know the exhaustion that comes with trying...
In 2022, a reanalysis of the largest antidepressant study ever conducted found that traditional antidepressant medications only relieve depression symptoms in about one-third of patients who take...
If you’re considering accelerated Transcranial Magnetic Stimulation (TMS) therapy, it’s important to understand how it works, what to expect, and whether it’s the right fit for you.
Transcranial magnetic stimulation (TMS) has been FDA-approved for treating major depressive disorder (MDD) since 2008 and is a well-established treatment option, especially for patients who haven’t...
Antidepressant medication is often the first treatment offered to patients with major depressive disorder. However, these medications are not as effective as once thought and frequently trigger...
Published peer-reviewed research shows that Cognitive FX treatment leads to meaningful symptom reduction in post-concussion symptoms for 77% of study participants. Cognitive FX is the only PCS clinic with third-party validated treatment outcomes.
READ FULL STUDY
